Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medacta GroupMEDGF +90.68%71 EV-to-EBITDA is 15.45 as of Aug. 04, 2026, which is 30% below its 10-year median of 21.94. GuruFocus rates MEDGF with a GF Score™ of 71/100 and a GF Value™ of $90.97 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 512 Medical Devices & Instruments companies, Medacta Group ranks worse than 54.69% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Medacta Group's enterprise value is $3,524.1 Mil.
Medacta Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $228.0 Mil. Therefore, Medacta Group's EV-to-EBITDA for today is 15.45.
The historical rank and industry rank for Medacta Group's EV-to-EBITDA or its related term are showing as below:
MEDGF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 15.24 Med: 21.94 Max: 38.8
Current: 15.24
During the past 11 years, the highest EV-to-EBITDA of Medacta Group was 38.80. The lowest was 15.24. And the median was 21.94.
MEDGF's EV-to-EBITDA is ranked worse than 54.69% of 512
companies
in the Medical Devices & Instruments industry
Industry Median: 14.44
vs MEDGF: 15.24
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Medacta Group (OTCPK:MEDGF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Medacta Group's PE Ratio (TTM) for today is calculated as:
Medacta Group's share price for today is $160.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Medacta Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $5.545.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Medacta Group's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Medacta Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medacta Group EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medacta Group's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Medacta Group's EV-to-EBITDA falls into.
Medacta Group's current Enterprise Value is $3,524.1 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Medacta Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $228.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medacta Group (MEDGF) has a EV-to-EBITDA of 15.45 as of Aug. 04, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Medacta Group. This is 30% below median its historical median of 21.94. Over the past decade, Medacta Group's EV-to-EBITDA has ranged from 15.24 to 38.80. According to the industry distribution chart, Medacta Group ranks #280 out of 512 companies in the Medical Devices & Instruments industry, placing it in the top 54.7%.
Is Medacta Group's EV-to-EBITDA too high?
Medacta Group's current EV-to-EBITDA of 15.45 is 30% below median its 10-year median of 21.94. Over the past 10 years, this metric has ranged from a low of 15.24 to a high of 38.80. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.44. Medacta Group's value of 15.45 is 7% above this industry median. Based on the distribution chart, Medacta Group ranks #280 out of 512 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Medacta Group has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medacta Group's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medacta Group ranks #280 out of 512 companies for EV-to-EBITDA. This places Medacta Group in the lower half of its industry. The industry median EV-to-EBITDA is 14.44. Medacta Group's value of 15.45 is 7% above this benchmark. Historically, Medacta Group's own EV-to-EBITDA has ranged from 15.24 to 38.80 over the past decade. While the company's 10-year median is 21.94 vs. the industry median of 14.44, Medacta Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.44, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medacta Group's current EV-to-EBITDA of 15.45 is 7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Medacta Group. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medacta Group's current EV-to-EBITDA is 15.45, which is 30% below median its own 10-year median of 21.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medacta Group stock overvalued right now?
Based on GuruFocus' analysis, Medacta Group (MEDGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $90.97, compared to a current price of $160.00 — trading 75.9% above its estimated fair value. The current EV-to-EBITDA is 15.45, which is 30% below median its 10-year median of 21.94 and 7% above the Medical Devices & Instruments industry median of 14.44. Medacta Group's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Medacta Group (MEDGF), the current EV-to-EBITDA is 15.45 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medacta Group (MEDGF) Overvalued in 2026?
Based on GuruFocus' analysis, Medacta Group stock appears to be overvalued.
The current stock price of $160.00 is trading 75.9% above its estimated GF Value™ of $90.97.
GuruFocus considers Medacta Group to be Significantly Overvalued.
Key valuation signals for MEDGF:
EV-to-EBITDA: 15.45 (30% below median its 10-year median of 21.94)
GF Value™: $90.97 vs. price of $160.00 (75.9% above fair value)
Industry Position: 7% above the Medical Devices & Instruments median (#280 of 512)
No single metric tells the full story. See the MEDGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medacta Group SA is involved in developing, manufacturing, and distributing orthopedic and neurosurgical medical devices. It specializes in the design, production, and distribution of personalized and sustainable solutions for joint replacement, sports medicine, and spine surgery. Medacta's product portfolio includes hip, knee, shoulder, and spine replacement solutions, along with a comprehensive range of sports medicine. Its products and surgical techniques are supported by an extensive program of surgeon education and engagement initiatives, enabling its offerings to be effective for the patient and surgeon. Geographically, the company derives maximum revenue from EMEA (which includes Europe, Middle East and Africa), followed by North America, Asia-Pacific, and the Latin America markets.
71GF Score
Get the complete analysis for MEDGF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEDGF has been successfully added to your 
